NIH Translational Research Success Stories - LBS-008

Lin Bioscience and Columbia Technology Ventures, currently participant in the NIH Blueprint Neurotherapeutics program, in 2017 Lin Bioscience licensed the intellectual property portfolioand associated development program for a promising first-in-class oral medication intended to slow or halt the progression of "dry" Age-Related Macular Degeneration (AMD). The company has completed LBS-008 Phase 1 clinical trials in 2020. Read more about the NIH Translational Research Success Stories.

The release as fetched from its publisher. linbioscience.com ↗